白井久美子 (Kumiko Shirai) - マイポータル

基本情報

所属: 大阪大学医学系研究科消化器内科学

研究者番号: 20992267
J-GLOBAL ID: 202301015582419227
researchmap会員ID: R000057035

論文

Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin-3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.

Emi Sometani, Kazuhiro Murai, Hayato Hikita, Jihyun Sung, Satoshi Muraoka, Hidenori Toyoda, Satoshi Tanaka, Takayuki Miyake, Shinji Kuriki, Kenji Fukumoto …

Hepatology research : the official journal of the Japan Society of Hepatology 2026年7月11日査読有り
Impact of Treatment Response to Anticoagulant Therapy on Liver-Related Events in Patients With Cirrhosis and Portal Vein Thrombosis.

Atsushi Maeda, Yuki Tahata, Hayato Hikita, Hisashi Ishida, Takayuki Yakushijin, Masanori Nakahara, Kazuyoshi Ohkawa, Fumihiko Nakanishi, Sadaharu Iio, Ryotaro Sakamori …

Hepatology research : the official journal of the Japan Society of Hepatology 2026年3月24日
NRF2-COX2-PGE 2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma.

Shuhei Yamamoto, Takahiro Kodama, Akifumi Kuwano, Kazuki Maesaka, Tomomi Yoshida-Hashidate, Hideo Shindou, Haruhiko Takeda, Kumiko Shirai, Yuta Myojin, Kazuhiro Murai …

Hepatology (Baltimore, Md.) 2026年1月15日
Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Chinatsu Nishioka, Yuki Tahata, Kazuki Maesaka, Machiko Kai, Kumiko Shirai, Kazuhiro Murai, Yuki Makino, Yoshinobu Saito, Yasutoshi Nozaki, Tasuku Nakabori …

PloS one 21(5) e0341395 2026年
Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage.

Akiyoshi Shimoda, Kazuhiro Murai, Hayato Hikita, Satoshi Minami, Takayuki Miyake, Shinji Kuriki, Emi Sometani, Jihyun Sung, Satoshi Shigeno, Yuichiro Higuchi …

PloS one 21(1) e0340023 2026年
Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma.

Kazuki Maesaka, Hayato Hikita, Yuki Tahata, Chinatsu Nishioka, Machiko Kai, Kumiko Shirai, Kazuhiro Murai, Yuki Makino, Yoshinobu Saito, Takahiro Kodama …

Journal of gastroenterology 61(1) 68-77 2026年1月
Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Kazuki Maesaka, Hayato Hikita, Machiko Kai, Yuki Tahata, Kumiko Shirai, Akira Doi, Kazuhiro Murai, Yoshinobu Saito, Ryoko Yamada, Takahiro Kodama …

Journal of gastroenterology and hepatology 40(10) 2580-2590 2025年10月
Folate receptor 1 is a stemness trait-associated diagnostic and prognostic marker for hepatocellular carcinoma.

Yuto Shiode, Takahiro Kodama, Yu Sato, Ryo Takahashi, Takayuki Matsumae, Kumiko Shirai, Akira Doi, Yuki Tahata, Hayato Hikita, Tomohide Tatsumi …

Biomarker research 13(1) 37-37 2025年3月4日
Complete Response of Hepatocellular Carcinoma With Inferior Vena Cava Tumor Thrombus and Right Atrium Involvement to Combined Radiotherapy and Immunotherapy: A Case Report.

Kazuma Daiku, Akira Nishio, Hayato Hikita, Akira Doi, Kazuhiko Hayashi, Seiya Kato, Yoichi Sasaki, Akiyoshi Shimoda, Shinnosuke Kudo, Kenji Fukumoto …

Gastro hep advances 4(5) 100634-100634 2025年
Factors involved in gastroesophageal varix‐related events in patients with hepatitis C virus‐related compensated and decompensated cirrhosis after direct‐acting antiviral therapy

Yuki Tahata, Hayato Hikita, Satoshi Mochida, Nobuyuki Enomoto, Norifumi Kawada, Akio Ido, Daiki Miki, Masayuki Kurosaki, Hitoshi Yoshiji, Ryotaro Sakamori …

Hepatology Research 55(3) 319-332 2024年10月29日
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs.

Emi Sometani, Hayato Hikita, Kazuhiro Murai, Hidenori Toyoda, Satoshi Tanaka, Tsugiko Oze, Jihyun Sung, Akiyoshi Shimoda, Makoto Fukuoka, Satoshi Shigeno …

Hepatology research : the official journal of the Japan Society of Hepatology 2024年9月18日査読有り
Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis.

Shusuke Kumazaki, Hayato Hikita, Yuki Tahata, Ji Hyun Sung, Kenji Fukumoto, Yuta Myojin, Sadatsugu Sakane, Kazuhiro Murai, Yoichi Sasaki, Kumiko Shirai …

Alimentary pharmacology & therapeutics 60(3) 327-339 2024年8月査読有り
Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD.

Sadatsugu Sakane, Hayato Hikita, Kumiko Shirai, Tatsuya Sakamoto, Ryohei Narumi, Jun Adachi, Naruyasu Kakita, Yukinori Yamada, Hidenori Toyoda, Hirokazu Takahashi …

Hepatology communications 8(6) 2024年6月1日査読有り
The serum tenascin C level is a marker of metabolic disorder-related inflammation affecting pancreatic cancer prognosis.

Katsuhiko Sato, Hayato Hikita, Minoru Shigekawa, Kazumasa Soma, Ryohei Yamauchi, Jihyun Sung, Seiya Kato, Yoichi Sasaki, Shinnosuke Kudo, Kenji Fukumoto …

Scientific reports 14(1) 12028-12028 2024年5月26日
Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis

Kumiko Shirai, Hayato Hikita, Ryotaro Sakamori, Akira Doi, Yuki Tahata, Sadatsugu Sakane, Yoshihiro Kamada, Kazuhiro Murai, Akira Nishio, Ryoko Yamada …

PLOS ONE 17(12) e0279416-e0279416 2022年12月21日査読有り
PTX3 Is an Adipose Tissue-Related Serum Marker for Pancreatic Cancer Cachexia Predicting Subsequent Muscle Mass and Visceral Fat Loss.

Katsuhiko Sato, Hayato Hikita, Minoru Shigekawa, Seiya Kato, Yoichi Sasaki, Kazuma Shinkai, Makoto Fukuoka, Shinnosuke Kudo, Yu Sato, Kenji Fukumoto …

Cancer science 113(12) 4311-4326 2022年9月8日査読有り
Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients

Kumiko Shirai, Hayato Hikita, Sadatsugu Sakane, Ryohei Narumi, Jun Adachi, Akira Doi, Satoshi Tanaka, Yuki Tahata, Ryoko Yamada, Takahiro Kodama …

PLOS ONE 17(7) e0271020-e0271020 2022年7月7日査読有り
Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination-authors' reply.

Yuta Myojin, Hayato Hikita, Yuki Tahata, Akira Doi, Seiya Kato, Yoichi Sasaki, Kumiko Shirai, Sadatsugu Sakane, Ryoko Yamada, Takahiro Kodama …

Alimentary pharmacology & therapeutics 55(8) 1061-1062 2022年4月査読有り
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.

Yuta Myojin, Hayato Hikita, Yuki Tahata, Akira Doi, Seiya Kato, Yoichi Sasaki, Kumiko Shirai, Sadatsugu Sakane, Ryoko Yamada, Takahiro Kodama …

Alimentary pharmacology & therapeutics 55(4) 422-433 2022年2月査読有り
White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in Mice.

Sadatsugu Sakane, Hayato Hikita, Kumiko Shirai, Yuta Myojin, Youichi Sasaki, Shinnosuke Kudo, Kenji Fukumoto, Naoki Mizutani, Yuki Tahata, Yuki Makino …

Cellular and molecular gastroenterology and hepatology 12(5) 1683-1699 2021年7月22日査読有り

もっとみる

MISC

進行肝細胞癌におけるデュルバルマブ+トレメリムマブ併用療法の治療効果を予測する血漿中TWEAKの臨床的意義

平尾建, 小玉尚宏, 明神悠太, 佐藤悠, 大工和馬, 高橋遼, 山本修平, 前阪和城, 白井久美子, 村井一裕 …

日本肝がん分子標的治療研究会プログラム・抄録集 33rd 2026年
FDA承認薬ライブラリースクリーニングによるリソソーム損傷を介してHBs抗原分泌を減少させる化合物の同定

村井一裕, 疋田隼人, 下田彬允, 三宅崇之, 栗木真治, 染谷愛美, 成志弦, 滋野聡, 白井久美子, 小玉尚宏 …

肝臓 66(Supplement 1) 2025年
全身の脂質代謝変動に着目した,肥満状態におけるエタノール摂取が肝障害に与える影響の検討

白井久美子, 疋田隼人, 前阪和城, 土居哲, 坂根貞嗣, 村井一裕, 田畑優貴, 齋藤義修, 小玉尚宏, 巽智秀 …

肝臓 66(Supplement 1) 2025年
転写因子TEAD阻害による肝細胞癌の治療の可能性についての検討

齋藤義修, 齋藤義修, 疋田隼人, 小玉尚宏, 白井久美子, 土居哲, 村井一裕, 田畑優貴, 重川稔, SCHWABE Robert …

日本消化器病学会雑誌(Web) 122 2025年
薬剤ライブラリースクリーニングによるリソソーム損傷を介したHBs抗原を減少させる化合物の同定

村井一裕, 疋田隼人, 下田彬允, 三宅崇之, 栗木真治, 染谷愛美, 成志弦, 滋野聡, 白井久美子, 小玉尚宏 …

日本消化器病学会雑誌(Web) 122 2025年
B型慢性肝炎患者の長期核酸アナログ製剤投与下における肝細胞癌リスク因子の検討

村井一裕, 疋田隼人, 山田涼子, 田畑優貴, 白井久美子, 土居哲, 齋藤義修, 小玉尚宏, 巽智秀, 竹原徹郎

日本内科学会雑誌 114 2025年
FDA APPROVED DRUG LIBRARY SCREENING TO IDENTIFY COMPOUNDS THAT REDUCE HBS ANTIGEN

Akiyoshi Shimoda, Hayato Hikita, Kazuhiro Murai, Takayuki Miyake, Shinji Kuriki, Emi Sometani, Jihyun Sung, Satoshi Shigeno, Kumiko Shirai, Yuki Tahata …

HEPATOLOGY 80 S211-S212 2024年10月
NRF2-MEDIATED IMMUNE COLD TUMOR MICROENVIRONMENT CONTRIBUTES TO RESISTANCE TO ATEZOLIZUMAB AND BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA

Shuhei Yamamoto, Takahiro Kodama, Kazuki Maesaka, Akifumi Kuwano, Kenta Motomura, Kumiko Shirai, Akira Doi, Kazuhiro Murai, Yuki Tahata, Yoshinobu Saito …

HEPATOLOGY 80 2024年10月
MALE SEX, HIGH β- GTP, HIGH AFP, HIGH GDF15 AND HIGH FIB-4 INDEX WERE HIGH RISK FACTORS FOR THE OCCURRENCE OF PRIMARY HCC IN CHB PATIENTS UNDER NUC TREATMENT

Kazuhiro Murai, Hayato Hikita, Emi Sometani, Satoshi Tanaka, Takayuki Miyake, Shinji Kuriki, Jihyun Sung, Akiyoshi Shimoda, Satoshi Shigeno, Kumiko Shirai …

HEPATOLOGY 80 S277-S278 2024年10月
TUMOR-DERIVED CIRCULATING CARBONIC ANHYDRASE 9 AS A PREDICTOR OF RESISTANCE TO ATEZOLIZUMAB AND BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA

Yu Sato, Takahiro Kodama, Machiko Kai, Kazuki Maesaka, Ryo Takahashi, Shuhei Yamamoto, Kumiko Shirai, Akira Doi, Kazuhiro Murai, Yuki Tahata …

HEPATOLOGY 80 S1501-S1501 2024年10月
REGNASE-1 DOWNREGULATION CONTRIBUTES TO MYELOID CELL INTERMEDIATED ICC DEVELOPMENT

Yu Sato, Takahiro Kodama, Yoshinobu Saito, Yuki Tahata, Kazuhiro Murai, Akira Doi, Kumiko Shirai, Kazuki Maesaka, Hayato Hikita, Tomohide Tatsumi …

HEPATOLOGY 80 S522-S523 2024年10月
Serum GDF15 level, in combination with the FIB-4 index, is useful for refining the identification of high-risk patients for clinical event occurrence in MASLD patients

Hayato Hikita, Shunsuke Kumazaki, Yuki Tahata, Ji Hyun Sung, Kenji Fukumoto, Yuta Myojin, Sadatsugu Sakane, Kazuhiro Murai, Yoichi Sasaki, Kumiko Shirai …

JOURNAL OF HEPATOLOGY 80 S506-S507 2024年6月
進行肝細胞癌に対する複合免疫療法効果予測因子かつ新規治療標的分子Carbonic anhydrase 9の同定と機能解析

佐藤悠, 小玉尚宏, 前阪和城, 甲斐真知子, 高橋遼, 山本修平, 白井久美子, 土居哲, 村井一浩, 田畑優貴 …

日本肝がん分子標的治療研究会プログラム・抄録集 31st 2024年
BINGE ALCOHOL INTAKE IN OBESITY INCREASES SERUM AND HEPATIC ETHYL ARACHIDONATE AND EXACERBATES LIVER INJURY

Kumiko Shirai, Hayato Hikita, Sadatsugu Sakane, Kazuhiro Murai, Akira Nishio, Kunimaro Furuta, Takahiro Kodama, Tomohide Tatsumi, Tetsuo Takehara

HEPATOLOGY 78 S1585-S1585 2023年10月
SERUM AMYLOID P COMPONENT AND PRO-PLATELET BASIC PROTEIN IN EXTRACELLULAR VESICLES OR SERUM ARE NOVEL MARKERS OF LIVER FIBROSIS

Kumiko Shirai, Hayato Hikita, Sadatsugu Sakane, Ryohei Narumi, Jun Adachi, Akira Doi, Satoshi Tanaka, Yuki Tahata, Ryoko Yamada, Takahiro Kodama …

HEPATOLOGY 76 S358-S359 2022年10月
SERUM Fibulin3 IS A NOVEL FIBROSIS MARKER IN NAFLD REVEALED BY PROTEOMIC ANALYSIS OF SERUM EXTRACELLULAR VESICLES.

Sadatsugu Sakane, Hayato Hikita, Kumiko Shirai, Ryohei Narumi, Jun Adachi, Ryotaro Sakamori, Naruyasu Kakita, Yukinori Yamada, Tatsuya Sakamoto, Machiko Kai …

HEPATOLOGY 76 S801-S801 2022年10月
GROWTH DIFFERENTIATION FACTOR 15 AS A NOVEL BIOMARKER FOR HEPATOCELLULAR CARCINOMA AFTER HCV ELIMINATION

Yuta Myojin, Hayato Hikita, Yuki Tahata, Akira Doi, Yoichi Sasaki, Kumiko Shirai, Sadatsugu Sakane, Ryoko Yamada, Takahiro Kodama, Ryotaro Sakamori …

HEPATOLOGY 74 543A-544A 2021年10月
RUBICON-INDEPENDENT AUTOPHAGY SUPPRESSION CAUSES LIVER INJURY IN ALCOHOLIC LIVER DISEASE.

Kumiko Shirai, Hayato Hikita, Sadatsugu Sakane, Shinnosuke Kudo, Yuta Myojin, Takahiro Kodama, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara

HEPATOLOGY 70 832A-833A 2019年10月
AUTOPHAGY SUPPRESSION IN ADIPOSE TISSUE AMELIORATES LIVER INJURY THOROUGH THE DECREASE OF SUBCUTANEOUS FAT LIPOLYSIS IN NAFLD/NASH MODEL.

Sadatsugu Sakane, Hayato Hikita, Kumiko Shirai, Yoichi Sasaki, Shinnosuke Kudo, Kenji Fukumoto, Naoki Mizutani, Yuta Myojin, Yuto Shiode, Yasutoshi Nozaki …

HEPATOLOGY 70 1291A-1291A 2019年10月
HCV-INFECTED HEPATOCYTES INHIBIT AUTOPHAGIC FLUX, WHICH IN TURN ACTIVATES Mx1 AND SUPPRESS HCV REPLICATION THROUGH UP-REGULATION OF RUBICON EXPRESSION

Yuto Shiode, Hayato Hikita, Kumiko Shirai, Yuta Myojin, Sadatsugu Sakane, Ryoko Yamada, Takahiro Kodama, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara

HEPATOLOGY 70 1001A-1002A 2019年10月

もっとみる

共同研究・競争的資金等の研究課題

ヒト肝細胞キメラマウスを用いたC型肝炎ウイルス排除後肝病態の解明

日本学術振興会科学研究費助成事業若手研究 2024年4月 - 2026年3月

白井久美子

白井久美子

基本情報

論文

MISC

共同研究・競争的資金等の研究課題

メニュー

共著者の一覧